Spur Therapeutics

Freeline is a clinical-stage biotechnology company that aims to develop transformative gene therapies for chronic debilitating diseases. The company's vision, as reflected in their slogan, is inspired by people with chronic diseases and made possible by their gene technology. Founded in 2015 and headquartered in the United Kingdom, Freeline utilizes its proprietary, rationally designed AAV vector and capsid (AAVS3), along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells. This methodology aims to express a persistent functional level of the missing or dysfunctional protein into a patient’s bloodstream. Currently, Freeline is advancing FLT201, a highly differentiated gene therapy candidate, in a Phase 1/2 clinical trial in people with Gaucher disease type 1. Furthermore, the company has additional programs in research, including one focused on GBA1-linked Parkinson’s disease that leverages the same novel transgene as FLT201. Their last investment of $26.10MPost-IPO Equity was made on 10 March 2022 and the investor was Syncona Investment Management. With a strong footing in the Biopharma, Biotechnology, and Health Care industries, Freeline is poised to make significant strides in the field of gene therapy.